Funder
National Institutes of Health
Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmacology,Genetics,Biochemistry
Reference93 articles.
1. Caminero JA, Scardigli A. Classification of antituberculosis drugs: a new proposal based on the most recent evidence. Eur Respir J. 2015;46(4):887–93.
2. Tiberi S, Scardigli A, Centis R, D’Ambrosio L, Muñoz-Torrico M, Salazar-Lezama MÁ, et al. Classifying new anti-tuberculosis drugs: rationale and future perspectives. Int J Infect Dis. 2017;56:181–4.
3. Isa SE, Ebonyi AO, Shehu NY, Idoko P, Anejo-Okopi JA, Simji G, et al. Antituberculosis drugs and hepatotoxicity among hospitalized patients in Jos, Nigeria. Int J Mycobacteriol. 2016;5(1):21–6.
4. WHO Guidelines Approved by the Guidelines Review Committee. In: Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Geneva: World Health Organization World Health Organization; 2011.
5. Chouchane S, Lippai I, Magliozzo RS. Catalase-peroxidase (mycobacterium tuberculosis KatG) catalysis and isoniazid activation. Biochemistry. 2000;39(32):9975–83.